Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort

M.J.L. Zuurhout; S.J.H. Vijverberg; J.A.M. Raaijmakers; L. Koenderman; D.S. Postma; G.H. Koppelman; A.H. Maitland-van der Zee

doi:10.2217/pgs.13.200

Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort

M.J.L. Zuurhout
, S.J.H. Vijverberg
, J.A.M. Raaijmakers
, L. Koenderman
, D.S. Postma
, G.H. Koppelman
, A.H. Maitland-van der Zee

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Current evidence suggests that asthma patients with the ADRB2 Arg16 genotype have a poorer response to long-acting β2-agonists (LABA), but the results remain inconsistent.

AIM: This study assessed the association between Arg16 variants and treatment outcome in children treated with inhaled corticosteroids (ICS) and LABA.

MATERIALS & METHODS: ADRB2 Arg16 was genotyped in 597 children (4-12 years of age) participating in the PACMAN cohort study. A questionnaire was used to assess asthma control, frequency of asthma-related emergency department visits and use of oral corticosteroids in the past year.

RESULTS: Arg/Arg carriers with a reported use of ICS and LABA had an increased risk of oral corticosteroid use (odds ratio: 14.9; 95% CI: 1.59-140.1) and emergency department visits in the past year (odds ratio: 11.9; 95% CI: 1.22-115.8) compared to Gly/Gly carriers. This effect was not observed in Arg/Arg genotype carriers reporting ICS use only.

CONCLUSION: Children who are homozygous for ADRB2 Arg16 have an increased risk of exacerbations when treated with combined LABA and ICS.

Original language	English
Pages (from-to)	1965-71
Number of pages	7
Journal	Pharmacogenomics
Volume	14
Issue number	16
DOIs	https://doi.org/10.2217/pgs.13.200
Publication status	Published - Dec 2013

Keywords

Administration, Inhalation
Adrenal Cortex Hormones
Adrenergic beta-2 Receptor Agonists
Anti-Asthmatic Agents
Asthma
Child
Child, Preschool
Female
Genotype
Homozygote
Humans
Male
Receptors, Adrenergic, beta-2
Risk Factors
Treatment Outcome

Access to Document

10.2217/pgs.13.200

Cite this

Zuurhout, M. J. L., Vijverberg, S. J. H., Raaijmakers, J. A. M., Koenderman, L., Postma, D. S., Koppelman, G. H., & Maitland-van der Zee, A. H. (2013). Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort. Pharmacogenomics, 14(16), 1965-71. https://doi.org/10.2217/pgs.13.200

@article{4f68b962fea847df97d8a520c58a50f7,

title = "Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort",

abstract = "BACKGROUND: Current evidence suggests that asthma patients with the ADRB2 Arg16 genotype have a poorer response to long-acting β2-agonists (LABA), but the results remain inconsistent.AIM: This study assessed the association between Arg16 variants and treatment outcome in children treated with inhaled corticosteroids (ICS) and LABA.MATERIALS \& METHODS: ADRB2 Arg16 was genotyped in 597 children (4-12 years of age) participating in the PACMAN cohort study. A questionnaire was used to assess asthma control, frequency of asthma-related emergency department visits and use of oral corticosteroids in the past year.RESULTS: Arg/Arg carriers with a reported use of ICS and LABA had an increased risk of oral corticosteroid use (odds ratio: 14.9; 95\% CI: 1.59-140.1) and emergency department visits in the past year (odds ratio: 11.9; 95\% CI: 1.22-115.8) compared to Gly/Gly carriers. This effect was not observed in Arg/Arg genotype carriers reporting ICS use only.CONCLUSION: Children who are homozygous for ADRB2 Arg16 have an increased risk of exacerbations when treated with combined LABA and ICS.",

keywords = "Administration, Inhalation, Adrenal Cortex Hormones, Adrenergic beta-2 Receptor Agonists, Anti-Asthmatic Agents, Asthma, Child, Child, Preschool, Female, Genotype, Homozygote, Humans, Male, Receptors, Adrenergic, beta-2, Risk Factors, Treatment Outcome",

author = "M.J.L. Zuurhout and S.J.H. Vijverberg and J.A.M. Raaijmakers and L. Koenderman and D.S. Postma and G.H. Koppelman and \{Maitland-van der Zee\}, A.H.",

year = "2013",

month = dec,

doi = "10.2217/pgs.13.200",

language = "English",

volume = "14",

pages = "1965--71",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis Ltd.",

number = "16",

}

TY - JOUR

T1 - Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists

T2 - results of the PACMAN cohort

AU - Zuurhout, M.J.L.

AU - Vijverberg, S.J.H.

AU - Raaijmakers, J.A.M.

AU - Koenderman, L.

AU - Postma, D.S.

AU - Koppelman, G.H.

AU - Maitland-van der Zee, A.H.

PY - 2013/12

Y1 - 2013/12

N2 - BACKGROUND: Current evidence suggests that asthma patients with the ADRB2 Arg16 genotype have a poorer response to long-acting β2-agonists (LABA), but the results remain inconsistent.AIM: This study assessed the association between Arg16 variants and treatment outcome in children treated with inhaled corticosteroids (ICS) and LABA.MATERIALS & METHODS: ADRB2 Arg16 was genotyped in 597 children (4-12 years of age) participating in the PACMAN cohort study. A questionnaire was used to assess asthma control, frequency of asthma-related emergency department visits and use of oral corticosteroids in the past year.RESULTS: Arg/Arg carriers with a reported use of ICS and LABA had an increased risk of oral corticosteroid use (odds ratio: 14.9; 95% CI: 1.59-140.1) and emergency department visits in the past year (odds ratio: 11.9; 95% CI: 1.22-115.8) compared to Gly/Gly carriers. This effect was not observed in Arg/Arg genotype carriers reporting ICS use only.CONCLUSION: Children who are homozygous for ADRB2 Arg16 have an increased risk of exacerbations when treated with combined LABA and ICS.

AB - BACKGROUND: Current evidence suggests that asthma patients with the ADRB2 Arg16 genotype have a poorer response to long-acting β2-agonists (LABA), but the results remain inconsistent.AIM: This study assessed the association between Arg16 variants and treatment outcome in children treated with inhaled corticosteroids (ICS) and LABA.MATERIALS & METHODS: ADRB2 Arg16 was genotyped in 597 children (4-12 years of age) participating in the PACMAN cohort study. A questionnaire was used to assess asthma control, frequency of asthma-related emergency department visits and use of oral corticosteroids in the past year.RESULTS: Arg/Arg carriers with a reported use of ICS and LABA had an increased risk of oral corticosteroid use (odds ratio: 14.9; 95% CI: 1.59-140.1) and emergency department visits in the past year (odds ratio: 11.9; 95% CI: 1.22-115.8) compared to Gly/Gly carriers. This effect was not observed in Arg/Arg genotype carriers reporting ICS use only.CONCLUSION: Children who are homozygous for ADRB2 Arg16 have an increased risk of exacerbations when treated with combined LABA and ICS.

KW - Administration, Inhalation

KW - Adrenal Cortex Hormones

KW - Adrenergic beta-2 Receptor Agonists

KW - Anti-Asthmatic Agents

KW - Asthma

KW - Child

KW - Child, Preschool

KW - Female

KW - Genotype

KW - Homozygote

KW - Humans

KW - Male

KW - Receptors, Adrenergic, beta-2

KW - Risk Factors

KW - Treatment Outcome

U2 - 10.2217/pgs.13.200

DO - 10.2217/pgs.13.200

M3 - Article

C2 - 24279851

SN - 1462-2416

VL - 14

SP - 1965

EP - 1971

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 16

ER -

Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort

Abstract

Keywords

Access to Document

Fingerprint

Cite this